Key Points
- General Counsel Ruben Garcia purchased 140,000 shares of FibroBiologics on December 11 at an average price of $0.34 per share for a total of $47,600, a transaction disclosed in an SEC filing.
- FibroBiologics is a microcap biotech (market capitalization ~$20.93 million) trading between $0.24 and $2.51 over the past 52 weeks, with a recent opening price of $0.39 and negative earnings (missed Q3 EPS of ($0.13)).
- Analyst sentiment is mixed—two firms rate the stock "Buy" and one "Sell," leaving an average MarketBeat rating of "Hold" and an average target price of $12.50.
FibroBiologics Inc. (NASDAQ:FBLG - Get Free Report) General Counsel Ruben Garcia purchased 140,000 shares of FibroBiologics stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the completion of the acquisition, the general counsel owned 140,000 shares of the company's stock, valued at approximately $47,600. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
FibroBiologics Stock Performance
FBLG stock opened at $0.39 on Friday. FibroBiologics Inc. has a 52-week low of $0.24 and a 52-week high of $2.51. The company has a market capitalization of $20.93 million, a P/E ratio of -0.82 and a beta of -0.58. The company has a fifty day moving average price of $0.36 and a 200-day moving average price of $0.55.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last released its earnings results on Friday, October 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.03). As a group, sell-side analysts forecast that FibroBiologics Inc. will post -0.53 earnings per share for the current fiscal year.
Analyst Ratings Changes
FBLG has been the topic of a number of recent research reports. D. Boral Capital reiterated a "buy" rating and issued a $15.00 target price on shares of FibroBiologics in a report on Thursday, November 20th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of FibroBiologics in a research note on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of FibroBiologics in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $12.50.
View Our Latest Stock Report on FibroBiologics
Institutional Investors Weigh In On FibroBiologics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ethos Financial Group LLC lifted its position in shares of FibroBiologics by 100.0% during the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company's stock worth $30,000 after buying an additional 24,424 shares in the last quarter. XTX Topco Ltd lifted its holdings in FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company's stock worth $29,000 after acquiring an additional 28,276 shares during the period. Cascade Financial Partners LLC boosted its position in FibroBiologics by 11.7% in the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company's stock worth $181,000 after purchasing an additional 30,500 shares during the last quarter. AQR Capital Management LLC purchased a new position in FibroBiologics in the first quarter worth $29,000. Finally, Nuveen LLC bought a new position in FibroBiologics in the 1st quarter valued at $31,000.
About FibroBiologics
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
